Introduction: Dr Love

• Introduction

Lung Cancer

• Chemotherapeutic and Immunotherapeutic Approaches to Wild-Type NSCLC, SCLC and Mesothelioma: Dr Rizvi
• Management of Patients with EGFR, ALK or ROS1 Alterations: Dr Oxnard
• Targeted Therapies for Uncommon Mutations in NSCLC; Novel Agents for SCLC: Dr Johnson

Breast Cancer

• Novel Chemotherapy Options, Immunotherapy and Treatment Strategies for HER2-Positive and Triple-Negative Breast Cancer: Dr Sledge
• Genomic Assays and Novel Treatment Strategies for ER-Positive Breast Cancer: Dr Gradishar

Melanoma

• Talimogene Laherparepvec, Single-Agent Checkpoint Inhibitor Data and Immune-Related Response Criteria in Melanoma: Dr Luke
• Combination Checkpoint Inhibitor Regimens; Treatment of BRAF V600- or NRAS-Mutant Melanoma: Dr Weber

Genitourinary Cancers

• Endocrine and Bone-Targeted Therapy for Prostate Cancer: Dr Quinn
• Novel Approaches to the Management of Renal Cell and Urothelial Bladder Cancer: Dr Plimack

Hodgkin and Non-Hodgkin Lymphomas

• Chronic Lymphocytic Leukemia: Dr Williams
• Follicular, Diffuse Large B-Cell and Mantle Cell Lymphomas; Dr Flinn
• Hodgkin and T-Cell Lymphomas: Dr Nastoupil

Multiple Myeloma

• Management of Newly Diagnosed Myeloma and Smoldering Myeloma: Dr Orlowski
• Management of Relapsed Myeloma and Incorporation of Novel Agents: Ixazomib, Daratumumab, Elotuzumab and Checkpoint Inhibitors: Dr Anderson

Colorectal, Gastric and Pancreatic Cancer

• Emerging Data on the Treatment of Metastatic Colorectal and Gastric Cancers: Dr Philip
• Emerging Treatment Options for Noncolorectal GI Cancers: Dr Bekaii-Saab

Bonus Content

• View In-Depth Commentary
  from Our Faculty